Adalimumab Concentration-based Tapering Strategy: As Good As the Recommended Dosage

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2018 Jan 8

PMID 29306871

Citations 6

Authors

Denis Mulleman

Alejandro Balsa

Affiliations

Soon will be listed here.

Citing Articles

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider.

Krieckaert C, Hernandez-Breijo B, Gehin J, Le Meledo G, Balsa A, Jani M RMD Open. 2022; 8(2).

PMID: 35980738 PMC: 9171282. DOI: 10.1136/rmdopen-2022-002216.

Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults.

Parikh C, Ponnampalam J, Seligmann G, Coelewij L, Pineda-Torra I, Jury E Ther Adv Musculoskelet Dis. 2021; 13:1759720X211002685.

PMID: 34188697 PMC: 8212384. DOI: 10.1177/1759720X211002685.

The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring.

Wadhwa M, Bird C, Atkinson E, Cludts I, Rigsby P Front Immunol. 2021; 12:636420.

PMID: 33936049 PMC: 8082443. DOI: 10.3389/fimmu.2021.636420.

Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations.

Bastida C, Huitema A, lAmi M, Ruiz-Esquide V, Wolbink G, Sanmarti R Eur J Clin Pharmacol. 2020; 76(10):1417-1425.

PMID: 32514745 DOI: 10.1007/s00228-020-02925-w.

Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis.

Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien T, de Longueville M Clin Transl Sci. 2020; 13(4):743-751.

PMID: 32100960 PMC: 7359948. DOI: 10.1111/cts.12760.

References

Ben-Horin S, Chowers Y . Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014; 11(4):243-55. DOI: 10.1038/nrgastro.2013.253. View

Medina F, Plasencia C, Goupille P, Ternant D, Balsa A, Mulleman D . Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis. Ther Drug Monit. 2017; 39(4):364-369. DOI: 10.1097/FTD.0000000000000421. View

Bartelds G, Wijbrandts C, Nurmohamed M, Stapel S, Lems W, Aarden L . Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007; 66(7):921-6. PMC: 1955110. DOI: 10.1136/ard.2006.065615. View

Darrouzain F, Bian S, Desvignes C, Bris C, Watier H, Paintaud G . Immunoassays for Measuring Serum Concentrations of Monoclonal Antibodies and Anti-biopharmaceutical Antibodies in Patients. Ther Drug Monit. 2017; 39(4):316-321. DOI: 10.1097/FTD.0000000000000419. View

Krieckaert C, Nair S, Nurmohamed M, van Dongen C, Lems W, Lafeber F . Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis. 2013; 74(2):361-8. DOI: 10.1136/annrheumdis-2013-204101. View

Bongartz T, Sutton A, Sweeting M, Buchan I, Matteson E, Montori V . Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295(19):2275-85. DOI: 10.1001/jama.295.19.2275. View

Plasencia C, Pascual-Salcedo D, Alcocer P, Bonilla M, Villalba A, Peiteado D . The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab. Ann Rheum Dis. 2013; 72(11):1888-90. DOI: 10.1136/annrheumdis-2013-203353. View

lAmi M, Krieckaert C, Nurmohamed M, van Vollenhoven R, Rispens T, Boers M . Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis. 2017; 77(4):484-487. DOI: 10.1136/annrheumdis-2017-211781. View

Bejan-Angoulvant T, Ternant D, Daoued F, Medina F, Bernard L, Mammou S . Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis. Arthritis Rheumatol. 2016; 69(1):108-113. DOI: 10.1002/art.39841. View

10.

Ducourau E, Ternant D, Lequerre T, Fuzibet P, Le Loet X, Watier H . Towards an individualised target concentration of adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2014; 73(7):1428-9. DOI: 10.1136/annrheumdis-2013-204971. View

11.

Garces S, Antunes M, Benito-Garcia E, da Silva J, Aarden L, Demengeot J . A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2013; 73(6):1138-43. DOI: 10.1136/annrheumdis-2013-203296. View

12.

van Herwaarden N, van den Bemt B, Wientjes M, Kramers C, den Broeder A . Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. Expert Opin Drug Metab Toxicol. 2017; 13(8):843-857. DOI: 10.1080/17425255.2017.1353602. View

13.

Telleman P, Junghans R . The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile. Immunology. 2000; 100(2):245-51. PMC: 2326999. DOI: 10.1046/j.1365-2567.2000.00034.x. View

14.

Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T . Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011; 70(7):1208-15. PMC: 3103666. DOI: 10.1136/ard.2011.153023. View

15.

Leombruno J, Einarson T, Keystone E . The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2008; 68(7):1136-45. DOI: 10.1136/ard.2008.091025. View

16.

Vogelzang E, Kneepkens E, Nurmohamed M, van Kuijk A, Rispens T, Wolbink G . Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis. 2014; 73(12):2178-82. DOI: 10.1136/annrheumdis-2014-205554. View

17.

Ordas I, Mould D, Feagan B, Sandborn W . Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012; 91(4):635-46. DOI: 10.1038/clpt.2011.328. View

18.

Pouw M, Krieckaert C, Nurmohamed M, van der Kleij D, Aarden L, Rispens T . Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2013; 74(3):513-8. DOI: 10.1136/annrheumdis-2013-204172. View

19.

van Schouwenburg P, Rispens T, Wolbink G . Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013; 9(3):164-72. DOI: 10.1038/nrrheum.2013.4. View

20.

Chen D, Chen Y, Hsieh T, Hung W, Hsieh C, Chen H . Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. Rheumatology (Oxford). 2015; 55(1):143-8. DOI: 10.1093/rheumatology/kev298. View